NCT00595114 is a clinical trial in Asthma, sponsored by Brigham and Women's Hospital.

Who is sponsoring NCT00595114?

NCT00595114 is sponsored by Brigham and Women's Hospital.

What condition does NCT00595114 study?

NCT00595114 studies Asthma, Pulmonary Disease, Chronic Obstructive.

Is NCT00595114 still recruiting?

NCT00595114 is currently completed. Last updated 4 September 2016.

Are results published for NCT00595114?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-09-04 · How we verify

NCT00595114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ancillary Study of Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease in the MIA (ACRN) and LEUKO (CCRN) Trials

Completed Results posted Last updated 4 September 2016

What this trial tests

trial in Asthma in 43 participants. Completed in 1 August 2009.

Timeline

1 December 2007

Primary endpoint
1 August 2009

1 August 2009

Quick facts

Lead sponsor	Brigham and Women's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	43
Start date	1 December 2007
Primary completion	1 August 2009
Estimated completion	1 August 2009
Sites	1 location across United States

Conditions studied

Asthma — all drugs for Asthma →
Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →

Sponsor

Brigham and Women's Hospital

Who can join

18 and older, any sex, with Asthma or Pulmonary Disease, Chronic Obstructive. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma
Time frame: Measured at completion of sample analysis
8-isoprostane levels in sputum

Sponsor's own description

Chronic obstructive pulmonary disease (COPD) and asthma are common respiratory diseases in which people experience long-term inflammation of the lungs. Exacerbations, or prolonged worsening of symptoms, of asthma and COPD are often life-threatening and can lead to frequent need for hospitalization. Even with the proper use of bronchodilators, corticosteroids, and other currently available medications, clinical responses among people with COPD and asthma are variable. There remains a significant unmet clinical need for new therapeutic approaches and insights, including the identification of biomarkers to accurately assess the presence of airway infection and intensity of airway inflammation. This study will investigate potential natural biological causes and new biomarkers for increased susceptibility to persistent airway infection in asthma and COPD.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma.
Ono E, Dutile S, Kazani S, Wechsler ME, et al · · 2014 · cited 66× · PMID 25162465 · DOI 10.1164/rccm.201403-0544oc

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Brigham and Women's Hospital trials

Trials by the same sponsor.

NCT07011758 — Dynamic Treatment Regimes for Opioid Use Disorder · Phase 2 · not yet recruiting
NCT06310018 — Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE · suspended
NCT04519177 — Randomized Trial of a Sleep Disorders Program on Firefighter Safety and Disability ... · NA · not yet recruiting
NCT06355986 — Computerized Decision Support to Prevent Stroke in Atrial Fibrillation · NA · not yet recruiting
NCT06099275 — Evaluation of Hemodynamics in People With Untreated Preeclampsia Using Echocardiography · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00595114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Brigham and Women's Hospital
Last refreshed: 4 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00595114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing